Tag Archives: request

J&J Earnings Beat Estimates; Guidance Raised As FX Headwinds Ease

Medical giant Johnson & Johnson ( JNJ ) beat Q1 estimates and raised guidance Tuesday morning, sending its stock to its fifth recent record high. J&J reported earnings of $1.68 a share, up 8% from the year-earlier quarter and beating analysts’ consensus by 3 cents, according to Thomson Reuters. Sales rose 0.6% to $17.48 billion, matching consensus. J&J said that the foreign-exchange impact knocked 6.6 percentage points off sales growth. Nonetheless, the forex headwinds finally seem to be abating. J&J cited the improved forex outlook as the reason it was raising full-year sales guidance by $400 million, to $71.2 billion to $71.9 billion. It also added 10 cents to EPS guidance, now $6.53 to $6.68. IBD’s Take: Johnson & Johnson rated No. 1 in its group, but CR is iffy . “Our Pharmaceuticals business continues to deliver impressive levels of growth, we have steady improvement in our Consumer business, and we are seeing momentum in our Medical Devices businesses, all of which are fueling our optimism for the full-year ahead,” J&J CEO Alex Gorsky said in a statement. J&J stock was up 2% in early trading on the stock market today , touching a record high of 113.60 intraday. The stock is up more than 10% for the year so far, and it is the first of three medical stocks that are hitting new highs  and are reporting this week, the others being Intuitive Surgical ( ISRG ) this evening and Stryker ( SYK ) late Wednesday. “This morning, J&J continued the growth momentum the company has seen in recent quarters, again delivering organic sales growth acceleration and its second consecutive quarter of double-digit EPS growth on an adjusted, operational basis,” wrote Leerink analyst Danielle Antalffy in a research note. She noted that, excluding the impact of foreign exchange, M&A activity and shrinking sales of hepatitis C drug Olysio — which was made obsolete when Gilead Sciences ( GILD ) released Harvoni in late 2014 — sales rose 6.9%. Operating EPS growth was just above 10%. Credit Suisse analyst Vamil Divan wrote that the pharma sales beat was driven by the immunology franchise — Remicade, Simponi and Stelara — as well as its stroke prevention treatment Xarelto. But another top seller, diabetes drug Invokana, missed consensus by 19%. Investors had been wondering if Invokana would take a hit from Eli Lilly ‘s ( LLY ) Jardiance, which last September proved that it could dramatically cut deaths from heart failure but didn’t get a sales bump from this in Q4.

Cable Firms Prepare To Fight Set-Top Rules That Help Google, Apple

Cable TV companies are readying a court challenge if the Federal Communications Commission approves new set-top box regulations that would let companies like Apple ( AAPL ), Alphabet ( GOOGL ), Amazon.com ( AMZN ) and others sell devices that provide access to cable programming. The National Cable & Telecommunications Association has hired Theodore Olson, an attorney at the noted law firm Gibson, Dunn & Crutcher, to battle the FCC’s set-top box proposal. Olson, a former solicitor general, represented George W. Bush in the contested 2000 election vs. Al Gore that ultimately was decided by the U.S. Supreme Court. Apple also recently hired Olson and Gibson, Dunn & Crutcher in its battle vs. the Federal Bureau of Investigation involving a court order to unlock an iPhone used by an assailant in the San Bernardino terror attack. President Obama last week stated his support for opening up the set-top box market for more competition. The proposal would require pay-TV and technology companies to jointly develop new standards for devices providing access to cable TV networks. The cable TV industry pays programmers billions of dollars for content rights, and it’s unclear how that business model would be impacted. Comcast ( CMCSA ) and phone company AT&T ( T ), also a pay-TV provider, have criticized the set-top box initiative. The FCC, with three Democratic members and two Republicans, is expected to vote on the plan after a public comment period closes. FCC Chairman Tom Wheeler says the plan will make it easier for consumers to switch from pay-TV companies’ set-top boxes leased monthly to new devices sold on a retail basis by consumer electronics or Internet companies. Gibson, Dunn ‘Most Certainly Preparing For Litigation’ “We are most certainly preparing for litigation in the event the FCC moves forward with its invasive and illegal plan to restructure the video programming market,” said a spokesperson for Gibson, Dunn & Crutcher. Brian Dietz, a NCTA spokesman said, “We are exploring all options.” The NCTA previously hired Gibson, Dunn & Crutcher to challenge the FCC’s Title II-based net neutrality rules that were enforced in mid-2015. The U.S. Court of Appeals for the District of Columbia Circuit is expected to rule soon on the net neutrality case. Pay-TV companies may have an uphill legal battle vs. the FCC’s set-top box rules, says Paul Gallant, an analyst at Guggenheim Partners. “Cable/telcos will almost certainly challenge any FCC final new set-top rules in court,” Gallant said in a February research report. “They will likely argue, among other things, that the FCC lacks authority to give app makers access to programming/guide information. “It’s far too early to predict the court outcome, but it’s important to note that the FCC is operating under a clear congressional mandate to make the set-top business competitive. That doesn’t necessarily mean the FCC will prevail, but the agency probably will feel good about its chances with that statutory starting point.” Under the proposed new set-top rules, the FCC says that only pay-TV subscribers will gain access to programming, and that copyright protections will be preserved. Google, critics say, aims to swap its own advertising for the local ads sold by cable TV companies.

3 Earnings Reports To Watch Tuesday: Yahoo, Intel, UnitedHealth

Yahoo ( YHOO ), Intel ( INTC ) and UnitedHealth ( UNH ) headline another busy day for earnings, though investors may look past headline EPS for all three industry giants. Yahoo Yahoo is expected to report a 53% year-over-year decline in EPS to 7 cents after the market close Tuesday. Revenue likely fell 12% to $1.08 billion, with revenue excluding traffic acquisition costs seen declining even faster. CEO Marissa Mayer has been unable to fuel significant growth since taking the helm in 2012. What investors will want to know is any information on the Yahoo bidding process, with offers due on Monday. Yahoo is entertaining offers for all or part of the Web portal, including its core U.S. operations and its Alibaba ( BABA ) stake. It’s unclear if Yahoo will say anything at all. Various reports said Verizon Communications ( VZ ) and YP Holdings, owned by Cerberus Capital and AT&T ( T ), are among the purported bidders . Yahoo stock rose 1 cent to 36.52 on the stock market today . Shares hit an 8-month high of 37.50 last week. Intel Intel also reports after Tuesday’s closing bell. Analysts expect EPS to rise 15% to 47 cents, with revenue up 8% to $13.83 billion. The key is to what extent data center chips offset weakness for PC chips. Investors will want to know if weak PC sales are continuing in Q2, and whether Intel will cut full-year guidance. Looking ahead, Apple may source 30 million to 40 million iPhone 7 modem chips from Intel, taking share from Qualcomm ( QCOM ), according to Canaccord analyst T. Michael Walkley. Qualcomm, which reports earnings Wednesday evening, will still get most of that business. Apple will release its iPhone 7 later this year. Intel rose 0.6% on Monday, find support just over its  200-day moving average. Qualcomm rose 1%, but remains in a downtrend going back to mid-2014. Apple fell 2.2%, continuing to fall after undercutting its 200-day line. UnitedHealth The No. 1 U.S. health insurer, and the first to report Q1 results, is due out Tuesday morning. Analysts expect an 18% EPS rise to $1.72, with revenue up 23% to $43.96 billion. Investors will looking for industry clues about membership, medical costs.  They’ll also want to know more about UnitedHealth’s plans for the ObamaCare exchange. UnitedHealth, which was cautious about entering these marketplaces, has been the most vocal about getting out, perhaps  entirely in 2017, due to ongoing losses. UnitedHealth last week announced it was exiting the Arkansas, Georgia and Michigan exchanges. If UnitedHealth drastically scales back its participation, it could reduce competition and boost premiums for enrollees. But if UnitedHealth spurs a stampede of insurers getting out, the impact could be huge. UnitedHealth stock rose to a new high a month ago, moving sideways since then. Shares rose 0.4% to 127.81 on Monday.